<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39430602</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2772-7076</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2024</Year><Month>Dec</Month></PubDate></JournalIssue><Title>IJID regions</Title><ISOAbbreviation>IJID Reg</ISOAbbreviation></Journal><ArticleTitle>Understanding the change of in-hospital mortality and respiratory failure between Delta and Omicron waves from a tertiary hospital in Southern Thailand: A retrospective cohort study.</ArticleTitle><Pagination><StartPage>100446</StartPage><MedlinePgn>100446</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100446</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijregi.2024.100446</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">This retrospective cohort study aims to assess the incidence and associated factors of in-hospital mortality and respiratory failure among patients with COVID-19 during the Omicron and Delta epidemics.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We reviewed medical records from a regional hospital in Southern Thailand of patients with COVID-19 during the Delta wave (August 2021 to December 2021) and the Omicron wave (February 2022 to June 2022). A computer-generated random sampling approach was used to select patients for analysis. Logistic regression identified factors associated with respiratory failure, while Cox proportional hazard models were used for in-hospital mortality associations.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Among 5729 hospitalized patients with COVID-19 (Delta: 1229; Omicron: 4500), 1164 were randomly sampled (Delta: 295; Omicron: 869). Patients during the Delta wave were older (median: 52.0; interquartile range: 31.5-70.0) compared with those during the Omicron wave (median: 37.0; interquartile range: 8.0-65.0), with lower rates of completed two doses of vaccination (Delta: 18.3%; Omicron: 51.8%). The Delta variant exhibited higher rates of respiratory failure (46.8% vs Omicron: 22.3%) and in-hospital mortality (12.5% vs Omicron: 6.9%). Increased age (adjusted odds ratio [aOR] 1.04, 95% confidence interval [CI] 1.03-1.04), severity at admission (aOR 12.48, 95% CI 7.21-22.22), and delayed time to admission (aOR 1.07, 95% CI 1.02-1.12) increased the risk of respiratory failure, while receiving two-dose vaccination reduced this risk (aOR 0.36, 95% CI 0.24-0.53). Similarly, increased age (adjusted hazard ratio [aHR] 1.05, 95% CI 1.03-1.06), severity at admission (aHR 7.20, 95% CI 4.09-12.60), and delayed time to admission (aHR 1.05, 95% CI 1.00-1.11) were associated with higher in-hospital mortality, with two-dose vaccination decreasing this risk (aHR 0.45, 95% CI 0.27-0.75).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">The Delta variant exhibited higher in-hospital mortality and respiratory failure rates compared with Omicron. The identification of high-risk groups emphasizes the critical need for timely care for vulnerable patients. Timely access to care and vaccination coverage are crucial in reducing respiratory failure and mortality due to COVID-19, highlighting the necessity for tailored interventions to mitigate the impact of emerging variants.</AbstractText><CopyrightInformation>© 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meesoontorn</LastName><ForeName>Supisara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hatyai Hospital, Department of Social Medicine, Hat Yai, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pakdee</LastName><ForeName>Wisitsak</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Prince of Songkla University, Faculty of Medicine, Department of Radiology, Hat Yai, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheranakhorn</LastName><ForeName>Chutima</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hatyai Hospital, Department of Internal Medicine, Hat Yai, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sangkaew</LastName><ForeName>Sorawat</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hatyai Hospital, Department of Social Medicine, Hat Yai, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Imperial College London, Faculty of Medicine, Department of Infectious Disease, Section of Adult Infectious Disease, London, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>IJID Reg</MedlineTA><NlmUniqueID>9918418183106676</NlmUniqueID><ISSNLinking>2772-7076</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Death</Keyword><Keyword MajorTopicYN="N">Hospitalization</Keyword><Keyword MajorTopicYN="N">Morbidity</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword></KeywordList><CoiStatement>The authors have no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>10</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>10</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>5</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39430602</ArticleId><ArticleId IdType="pmc">PMC11490909</ArticleId><ArticleId IdType="doi">10.1016/j.ijregi.2024.100446</ArticleId><ArticleId IdType="pii">S2772-7076(24)00117-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. Coronavirus (COVID-19) Dashboard, https://covid19.who.int; 2023 [accessed 27 November 2023].</Citation></Reference><Reference><Citation>Lauring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, McNeal T, et al. Clinical severity of, and effectiveness of mRNA vaccines against, Covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022;376 doi: 10.1136/bmj-2021-069761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-069761</ArticleId><ArticleId IdType="pmc">PMC8905308</ArticleId><ArticleId IdType="pubmed">35264324</ArticleId></ArticleIdList></Reference><Reference><Citation>Radhakrishnan N, Liu M, Idowu B, Bansari A, Rathi K, Magar S, et al. Comparison of the clinical characteristics of SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) infected patients from a single hospitalist service. BMC Infect Dis. 2023;23:747. doi: 10.1186/s12879-023-08714-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08714-x</ArticleId><ArticleId IdType="pmc">PMC10617227</ArticleId><ArticleId IdType="pubmed">37907849</ArticleId></ArticleIdList></Reference><Reference><Citation>Auvigne V, Vaux S, Strat YL, Schaeffer J, Fournier L, Tamandjou C, et al. Severe hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants in France, December 2021–January 2022: a retrospective, population-based, matched cohort study. EClinicalmedicine. 2022;48 doi: 10.1016/j.eclinm.2022.101455.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101455</ArticleId><ArticleId IdType="pmc">PMC9121907</ArticleId><ArticleId IdType="pubmed">35611065</ArticleId></ArticleIdList></Reference><Reference><Citation>Skarbinski J, Wood MS, Chervo TC, Schapiro JM, Elkin EP, Valice E, et al. Risk of severe clinical outcomes among persons with SARS-CoV-2 infection with differing levels of vaccination during widespread Omicron (B.1.1.529) and Delta (B.1.617.2) variant circulation in Northern California: a retrospective cohort study. Lancet Reg Health Am. 2022;12 doi: 10.1016/j.lana.2022.100297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2022.100297</ArticleId><ArticleId IdType="pmc">PMC9212563</ArticleId><ArticleId IdType="pubmed">35756977</ArticleId></ArticleIdList></Reference><Reference><Citation>Puenpa J, Rattanakomol P, Saengdao N, Chansaenroj J, Yorsaeng R, Suwannakarn K, et al. Molecular characterisation and tracking of severe acute respiratory syndrome coronavirus 2 in Thailand, 2020–2022. Arch Virol. 2023;168:26. doi: 10.1007/s00705-022-05666-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-022-05666-6</ArticleId><ArticleId IdType="pmc">PMC9807426</ArticleId><ArticleId IdType="pubmed">36593392</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheranakhorn C, Chanchaichujit T, Khunpakdee R. Use of delta modified search out severity (ΔM-SOS) score for early detect clinical deterioration in mechanically ventilated patients. J Med Assoc Thai. 2021;104:219–224. doi: 10.35755/jmedassocthai.2021.02.11482.</Citation><ArticleIdList><ArticleId IdType="doi">10.35755/jmedassocthai.2021.02.11482</ArticleId></ArticleIdList></Reference><Reference><Citation>Suwatanapongched T, Nitiwarangkul C, Arnuntasupakul V, Kiertiburanakul S. Rama Co-RADS: cutting-edge tool for improved communication in management and treatment of COVID-19 patients in Thailand. Asean J Radiol. 2021;22:29–49. doi: 10.46475/aseanjr.v22i2.144.</Citation><ArticleIdList><ArticleId IdType="doi">10.46475/aseanjr.v22i2.144</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanto TA, Lugito NPH, Hwei LRY, Virliani C, Octavius GS. Prevalence and determinants of COVID-19 vaccine acceptance in South East Asia: a systematic review and meta-analysis of 1,166,275 respondents. Trop Med Infect Dis. 2022;7:361. doi: 10.3390/tropicalmed7110361.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/tropicalmed7110361</ArticleId><ArticleId IdType="pmc">PMC9696885</ArticleId><ArticleId IdType="pubmed">36355903</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID19 Vaccine Tracker. Thailand, https://covid19.trackvaccines.org/country/thailand/; 2024 [accessed 11 April 2024].</Citation></Reference><Reference><Citation>Department of Disease Control. COVID-19 vaccine progress, https://ddc.moph.go.th/vaccine-covid19/; 2024 [accessed 11 April 2024].</Citation></Reference><Reference><Citation>Kitro A, Sirikul W, Piankusol C, Rirermsoonthorn P, Seesen M, Wangsan K, et al. Acceptance, attitude, and factors affecting the intention to accept COVID-19 vaccine among Thai people and expatriates living in Thailand. Vaccine. 2021;39:7554–7561. doi: 10.1016/j.vaccine.2021.11.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.11.031</ArticleId><ArticleId IdType="pmc">PMC8595590</ArticleId><ArticleId IdType="pubmed">34819224</ArticleId></ArticleIdList></Reference><Reference><Citation>Sila T, Suriyaamorn W, Toh C, Rajborirug S, Surasombatpattana S, Thongsuksai P, et al. Factors associated with the worsening of COVID-19 symptoms among cohorts in community- or home-isolation care in southern Thailand. Front Public Health. 2024;12 doi: 10.3389/fpubh.2024.1350304.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2024.1350304</ArticleId><ArticleId IdType="pmc">PMC10987961</ArticleId><ArticleId IdType="pubmed">38572011</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanneti NS, Patel AK, Tan LH, Marques AD, Perera RAPM, Sherrill-Mix S, et al. Comparison of SARS-CoV-2 variants of concern in primary human nasal cultures demonstrates Delta as most cytopathic and Omicron as fastest replicating. mBio. 2024;15 doi: 10.1128/mbio.03129-23. 03129–23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.03129-23</ArticleId><ArticleId IdType="pmc">PMC11005367</ArticleId><ArticleId IdType="pubmed">38477472</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero Starke KR, Reissig D, Petereit-Haack G, Schmauder S, Nienhaus A, Seidler A. The isolated effect of age on the risk of COVID-19 severe outcomes: a systematic review with meta-analysis. BMJ Glob Health. 2021;6 doi: 10.1136/bmjgh-2021-006434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-006434</ArticleId><ArticleId IdType="pmc">PMC8678541</ArticleId><ArticleId IdType="pubmed">34916273</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>